Zolgensma® & Piqray® FDA approvals

Investor Relations
Vas Narasimhan, CEO, Novartis
Paul Hudson, CEO, Novartis Pharmaceuticals
Dave Lennon, President, AveXis

May 27, 2019
Disclaimer

This presentation contains forward-looking statements, including "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "expected," "will," "planned," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Zolgensma®, or regarding potential future revenues from this product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Zolgensma® or Piqray® will be submitted or approved in any additional market, or at any particular time. Nor can there be any guarantee that Zolgensma® or Piqray® will be commercially successful in the future. In particular, our expectations regarding this product could be affected by, among other things, regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data, as well as the planned clinical trials of these products, and the length of time such planned clinical trials may take; the particular prescribing preferences of physicians and patients, including uncertainties as to whether physicians and patients would adopt Zolgensma® or Piqray® into their treatment regimens; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; general economic and industry conditions, including the effects of the persistently weak economic and financial environment in many countries; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise.
Zolgensma®
Zolgensma® the first-ever gene therapy for spinal muscular atrophy (SMA)

- Indicated for the treatment of pediatric patients less than 2 years of age with SMA
- Approved by FDA ahead of PDUFA date under Priority Review
- Rare Pediatric Priority Review voucher granted
- Launching immediately with product available to ship within the next 2 weeks

Please read full Prescribing Information for Zolgensma®, including Boxed Warning for Acute Serious Liver Injury.
Zolgensma® approved by FDA for a broad range of pediatric patients with SMA

Indication statement

Zolgensma® (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Target patient population

- <2 years of age
- Genetic diagnosis of SMA (regardless of SMN2 copy number)
- Symptomatic or pre-symptomatic

---

1. US Prescribing Information.
Zolgensma® delivered event-free survival, rapid improvement in motor function, and transformative and sustained milestone achievements

<table>
<thead>
<tr>
<th>Event-free survival</th>
<th>Motor function (CHOP-INTEND)</th>
<th>Milestone achievement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Natural history</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25% at 13.6 months</td>
<td>Always decline in score</td>
<td>Never achieve the ability to sit without support¹</td>
</tr>
<tr>
<td>8% at 20 months¹</td>
<td>Almost none reach a CHOP-INTEND score of ≥40 after 6 months of age⁴</td>
<td></td>
</tr>
<tr>
<td><strong>STR1VE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>87% at 13.6 months²³</td>
<td>+6.9 points from baseline one month post-treatment⁵</td>
<td>50% sitting without support ≥30 seconds at a mean of 8 months post-treatment (study ongoing)³</td>
</tr>
<tr>
<td></td>
<td>95% achieved a score ≥40 points³</td>
<td></td>
</tr>
<tr>
<td><strong>START</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic-dose Cohort</td>
<td>100% at 24 months³</td>
<td>75% sitting ≥ 30 seconds⁴</td>
</tr>
<tr>
<td></td>
<td>+9.8 points from baseline one month post-treatment³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>92% achieved a score ≥40 points³</td>
<td></td>
</tr>
</tbody>
</table>


¹ Finkel RS, et al. Neurology 2014;83(9):810–817. ² 13 of 15 patients (87%) who had reached 13.6 months of age or discontinued the study prior to 13.6 months were surviving without permanent ventilation. ³ In long-term follow-up, no previously achieved motor milestone has been lost (mean 3.7 years post-treatment)³
Requirements for initiation and monitoring

Prior to treatment
- Anti-AAV9 antibody titer screen (~2-day turnaround\(^1\))
- Assess liver function by clinical examination and by laboratory testing
- Baseline platelets and troponin-I
- Start steroid course at 1mg/kg/day (1-day prior to treatment)

Treatment day
- One-time, one-hour IV infusion
- Outpatient administration

Post-treatment
- Continue steroids for at least 1 month at 1 mg/kg/day; Assess liver function weekly the 1\(^{st}\) month, every other week 2\(^{nd}\), 3\(^{rd}\) months
- When results of clinical examination and lab testing of liver function are unremarkable, begin steroid taper over next 28 days
- Also assess platelets and troponin-I for 3 months

Please read full Prescribing Information for Zolgensma\(^\circledR\), including Boxed Warning for Acute Serious Liver Injury.

\(^{1}\)Based on experience in Managed Access Program.
Commercial presentation customized for each patient

- Dosed in 0.5kg increments from 2.6-13.5kg based on kits of 2-9 vials\(^1\)
- Individual patient kits prepared and shipped from FDA-approved gene therapy manufacturing site in Libertyville, IL
- Shipped on dry ice chain using custom, GPS-tracked, temperature-controlled SavSu shippers using single courier partner

---

1. US Prescribing Information.
Zolgensma® highly cost-effective at USD 2.125m

Available at USD 425K per year for 5 years in installment plan

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>50%</td>
<td>Below the ultra-rare cost-effectiveness threshold&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>50%</td>
<td>Below the 10-year cost of current chronic SMA drug&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>50%</td>
<td>Below the 10-year costs of 5 genetic, pediatric, ultra-orphan treatments&lt;sup&gt;3*&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Backed by five-year outcomes-based agreements, supported by contracting programs

---

1. ICER. Spinraza® and Zolgensma® for Spinal Muscular Atrophy: Effectiveness and Value. Feb. 22, 2019 Spinraza® is a registered trademark of Biogen.  
2. Spinraza® WAC.  
3. Estim. 10-year cumulative cost based on likely starting age and weight, published dosing guidelines, and per unit WAC cost of therapy by product. Strensiq®, Soliris®, Vimizim®, Cerezyme® and HEMLIBRA® Before rebates/discounts. Per package/vial costs from RED BOOK (IBM Watson Health), accessed 2/4/2019. Before rebates/discount. *Strensiq® is a registered trademark of Alexion Pharmaceuticals Inc. Soliris® is a registered trademark of Alexion Pharmaceuticals Inc. Cerezyme® is a registered trademark of Genzyme Corporation. HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
### Strong indicators for marketplace readiness: lab testing, distribution, institutions

<table>
<thead>
<tr>
<th>Physician specialist identifies patient</th>
<th>OneGene Program™ processes request</th>
<th>Insurance approvals</th>
<th>Institution administers therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirm genetic diagnosis, test for anti-AAV9 antibody and other labs</td>
<td>Conduct benefits investigation</td>
<td>Once payer has approved the Prior Authorization, the physician will be notified</td>
<td>Receives and prepares therapy</td>
</tr>
<tr>
<td>Sends Rx to OneGene Program™</td>
<td>Coordinates financial support for eligible patients</td>
<td>OneGene Program™ will coordinate shipment based on dosing date</td>
<td>Infuses therapy: one-time, 60-min infusion in outpatient setting</td>
</tr>
</tbody>
</table>

- >60 patient anti-AAV9 antibody tests run with ~2-day turnaround<sup>1</sup>
- >45 simulated orders and test shipments completed
- >15 payers in advanced discussion of terms
- ~40 institutions ready; 75% have administered therapy<sup>1</sup>

---

<sup>1</sup> Based on experience in Managed Access Program. Contracted turnaround is <4 days.

---

<sup>1</sup> Zolgensma<sup>®</sup> / Piqray<sup>®</sup> FDA approvals | Novartis Investor Relations | May 27, 2019
Zolgensma® production ready for launch and expanding further

Ready for launch

Illinois site approved by FDA for commercial gene therapy manufacturing

Commercial production batches being accumulated since January

Accelerated release protocol agreed with FDA

3 additional sites under development for expansion (AveXis North Carolina & Colorado sites, and third-party CMO)
Potential eligible Zolgensma® patients at launch

Prevalent SMA
- Approx. 700 prevalent\(^2\)
- Previously diagnosed
- Potentially on Spinraza®

Incident SMA
- Approx. 400 patients\(^1\)
- ~30 newly diagnosed per month

1. Assumes 1 in 8,000 SMA births per year. Includes newborn screening diagnosed patients with 2 & 3 SMN2 copy number and symptomatically diagnosed Type 1 & 2 infants. 2. Includes infants diagnosed prior to Zolgensma® launch in the last 2 years. Spinraza® is a registered trademark of Biogen.
Zolgensma® sets new standard as first-and-only, one-time gene therapy for SMA

- Broad label covering all SMA under the age of 2, including pre-symptomatic
- Rapid motor function improvements, unprecedented event-free survival and sustained milestone achievements compared to natural history
- Price significantly discounted vs chronic therapy costs; flexible options in place to support patient access
- Ready to launch with adequate supply
Next pioneering medicine, Piqray®, the first and only therapy for aBC patients with PIK3CA mutation

- Approved for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen¹
- ~40% of HR+/HER2- advanced breast cancer patients may face worse disease prognosis due to presence of PIK3CA mutations⁵-⁹
- Nearly doubled median PFS in HR+/HER2- aBC patients with a PIK3CA mutation compared to fulvestrant alone¹-⁴

The most common adverse reactions including laboratory abnormalities on the alpelisib plus fulvestrant arm were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma glutamyl transferase, nausea, increased alanine aminotransferase, fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time (aPTT), and alopecia. Full safety can be found at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf

1. Piqray (alpelisib) Prescribing Information. East Hanover., New Jersey, USA: Novartis Pharmaceuticals Corporation; May 2019. 2. André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen¹
First new drug application approved under the FDA Oncology Center of Excellence Real-Time Oncology Review pilot program

Launched with FDA approved companion diagnostic for PIK3CA testing (Qiagen)

US supply ready for commercial sale

Entered into agreement with Foundation Medicine to develop plasma and tissue test

Engaged with payers covering over 80% of the target population in the US

Continuing to investigate Piqray® in other PIK3CA mutation driven disease states
Q&A